Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

   Terminated · Phase 3 · MAC Lung Disease

   NCT06418711 · Mannkind Corporation · 48 U.S. investigators

   $2.2Mresearch payments

2. Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents

   Active, not recruiting · Phase 3 · Pneumococcal Infections

   NCT06838000 · Sanofi Pasteur Inc. · 22 U.S. investigators

   $2.1Mresearch payments

3. Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma

   Active, not recruiting · Phase 2 · Follicular Lymphoma

   NCT05994235 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

   $2.1Mresearch payments

4. A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

   Active, not recruiting · Phase 2 · Idiopathic Hypersomnia

   NCT06843590 · Alkermes, Inc. · 36 U.S. investigators

   $2.1Mresearch payments

5. The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

   Completed · Phase 3 · Influenza, Human

   NCT06015282 · Seqirus USA Inc · 52 U.S. investigators

   $2.1Mresearch payments

6. Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

   Active, not recruiting · Not applicable · Persistent Atrial Fibrillation

   NCT06096337 · Boston Scientific Corporation · 46 U.S. investigators

   $2.1Mresearch payments

7. A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

   Active, not recruiting · Phase 4 · Pulmonary Arterial Hypertension

   NCT05203510 · United Therapeutics Corporation · 29 U.S. investigators

   $2.1Mresearch payments

8. A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)

   Completed · Phase 2 · Narcolepsy Type 1

   NCT06358950 · Alkermes, Inc. · 37 U.S. investigators

   $2.1Mresearch payments

9. Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

   Completed · Phase 1 · Zika

   NCT06334393 · Valneva Austria GmbH · 4 U.S. investigators

   $2.0Mresearch payments

10. Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

    Recruiting · Phase 3 · Chronic Obstructive Pulmonary Disease

    NCT07190209 · Sanofi US Services Inc. · 86 U.S. investigators

    $2.0Mresearch payments

11. Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

    Recruiting · Phase 2 · Generalized Anxiety Disorder (GAD)

    NCT06846320 · AbbVie Inc. · 53 U.S. investigators

    $2.0Mresearch payments

12. Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

    Recruiting · Phase 2, Phase 3 · Advanced Non-Small Cell Lung Cancer

    NCT04613596 · Mirati Therapeutics, Inc. · 57 U.S. investigators

    $2.0Mresearch payments

13. A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age

    Completed · Phase 3 · Respiratory Syncytial Virus

    NCT05330975 · ModernaTX, Inc. · 38 U.S. investigators

    $2.0Mresearch payments

14. Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial

    Completed · Phase 4 · Diabetic Retinopathy

    NCT04708145 · Regeneron Pharmaceuticals, Inc. · 1 U.S. investigator

    $2.0Mresearch payments

15. A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

    Completed · Phase 2 · Bronchiectasis

    NCT06280391 · Sanofi US Services Inc. · 28 U.S. investigators

    $2.0Mresearch payments

16. Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

    Completed · Phase 3 · Contraception

    NCT05139121 · Mylan Inc. · 69 U.S. investigators

    $2.0Mresearch payments

17. A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

    Active, not recruiting · Phase 3 · Gastrointestinal Stromal Tumors

    NCT03673501 · Deciphera Pharmaceuticals Inc. · 13 U.S. investigators

    $1.9Mresearch payments

18. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

    Recruiting · Phase 3 · Migraine

    NCT05125302 · AbbVie Inc. · 113 U.S. investigators

    $1.9Mresearch payments

19. Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism

    Enrolling by invitation · Phase 2 · Trauma Injury

    NCT05794165 · Grifols Shared Services North America, Inc. · 4 U.S. investigators

    $1.9Mresearch payments

20. Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

    Enrolling by invitation · Phase 3 · Migraine

    NCT05127954 · AbbVie Inc. · 99 U.S. investigators

    $1.9Mresearch payments

21. A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

    Recruiting · Phase 1 · Advanced Solid Tumor

    NCT05981703 · Beigene, Ltd. · 5 U.S. investigators

    $1.9Mresearch payments

22. A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

    Completed · Phase 3 · Psoriatic Arthritis

    NCT06624228 · UCB SA · 38 U.S. investigators

    $1.9Mresearch payments

23. A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

    Completed · Phase 2 · Dermatitis Atopic

    NCT06015308 · Sanofi US Services Inc. · 45 U.S. investigators

    $1.9Mresearch payments

24. A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)

    Completed · Phase 1, Phase 2 · Atopic Dermatitis

    NCT05277571 · UCB SA · 18 U.S. investigators

    $1.9Mresearch payments

25. A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

    Recruiting · Phase 2, Phase 3 · Narcolepsy Type 1

    NCT06767683 · Alkermes, Inc. · 36 U.S. investigators

    $1.9Mresearch payments

26. Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)

    Completed · Phase 2 · Postural Orthostatic Tachycardia Syndrome (POTS)

    NCT06593600 · Regeneron Pharmaceuticals, Inc. · 17 U.S. investigators

    $1.9Mresearch payments

27. Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

    Completed · Phase 3 · Mycobacterium Infections, Nontuberculous

    NCT04677569 · Insmed, Inc. · 69 U.S. investigators

    $1.8Mresearch payments

28. A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

    Completed · Phase 3 · PAH

    NCT03626688 · United Therapeutics Corporation · 51 U.S. investigators

    $1.8Mresearch payments

29. A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

    Completed · Phase 4 · Moderate Plaque Psoriasis

    NCT06333860 · AbbVie Inc. · 43 U.S. investigators

    $1.8Mresearch payments

30. A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

    Terminated · Phase 1 · Solid Tumor

    NCT05578092 · E.r. Squibb & Sons, L.l.c. · 17 U.S. investigators

    $1.8Mresearch payments

31. A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

    Completed · Phase 1, Phase 2 · Influenza Immunization

    NCT06361875 · Sanofi Pasteur Inc. · 21 U.S. investigators

    $1.8Mresearch payments

32. A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

    Completed · Phase 3 · Obesity

    NCT05931367 · Eli Lilly and Company · 21 U.S. investigators

    $1.8Mresearch payments

33. A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

    Active, not recruiting · Phase 3 · Chronic Migraine

    NCT04616326 · Eli Lilly and Company · 38 U.S. investigators

    $1.8Mresearch payments

34. Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

    Recruiting · Phase 2 · Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    NCT06134232 · Dendreon Pharmaceuticals LLC · 43 U.S. investigators

    $1.8Mresearch payments

35. A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

    Recruiting · Phase 1, Phase 2 · Melanoma

    NCT06413680 · Regeneron Pharmaceuticals, Inc. · 12 U.S. investigators

    $1.8Mresearch payments

36. Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

    Recruiting · Not applicable · Heart Failure

    NCT05677100 · Procyrion, Inc. · 51 U.S. investigators

    $1.8Mresearch payments

37. Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

    Active, not recruiting · Phase 3 · Ovarian Cancer

    NCT05445778 · AbbVie Inc. · 54 U.S. investigators

    $1.8Mresearch payments

38. A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence

    Completed · Phase 3 · Masseter Muscle Prominence

    NCT06387394 · AbbVie Inc. · 21 U.S. investigators

    $1.8Mresearch payments

39. A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

    Active, not recruiting · Phase 4 · Type 2 Diabetes

    NCT05433584 · Eli Lilly and Company · 34 U.S. investigators

    $1.8Mresearch payments

40. A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

    Active, not recruiting · Phase 2 · B-cell Non-Hodgkin Lymphoma (B-NHL)

    NCT03888105 · Regeneron Pharmaceuticals, Inc. · 12 U.S. investigators

    $1.7Mresearch payments

41. A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

    Recruiting · Phase 3 · Alopecia Areata

    NCT06012240 · AbbVie Inc. · 70 U.S. investigators

    $1.7Mresearch payments

42. A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

    Active, not recruiting · Eosinophilic Esophagitis (EoE)

    NCT06693531 · Regeneron Pharmaceuticals, Inc. · 43 U.S. investigators

    $1.7Mresearch payments

43. A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

    Active, not recruiting · Phase 1 · Follicular Lymphoma

    NCT05934838 · Ipsen Biopharmaceuticals, Inc · 4 U.S. investigators

    $1.7Mresearch payments

44. A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

    Completed · Phase 1, Phase 2 · Chronic Lymphocytic Leukemia

    NCT03740529 · Eli Lilly and Company · 32 U.S. investigators

    $1.7Mresearch payments

45. A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy

    Active, not recruiting · Phase 2, Phase 3 · Primary Membranous Nephropathy

    NCT05707377 · Beigene, Ltd. · 11 U.S. investigators

    $1.7Mresearch payments

46. First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

    Terminated · Phase 1, Phase 2 · Acute Lymphocytic Leukaemia

    NCT05086315 · Sanofi US Services Inc. · 11 U.S. investigators

    $1.7Mresearch payments

47. TheraSphere With Durvalumab and Tremelimumab for HCC

    Active, not recruiting · Phase 2 · Hepatocellular Carcinoma

    NCT05063565 · Boston Scientific Corporation · 15 U.S. investigators

    $1.7Mresearch payments

48. Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

    Completed · Phase 3 · Hyperphagia in Prader-Willi Syndrome

    NCT06173531 · Acadia Pharmaceuticals Inc · 23 U.S. investigators

    $1.7Mresearch payments

49. An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

    Enrolling by invitation · Phase 3 · Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

    NCT05667493 · Ionis Pharmaceuticals, Inc. · 45 U.S. investigators

    $1.7Mresearch payments

50. A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

    Recruiting · Phase 2 · Follicular Lymphoma

    NCT05389293 · Beone Medicines USA, Inc. · 1 U.S. investigator

    $1.7Mresearch payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.